JPMorgan Chase & Co. Lowers Teladoc Health (NYSE:TDOC) Price Target to $33.00

Teladoc Health (NYSE:TDOC – Get Rating) had its price target cut by stock analysts at JPMorgan Chase & Co. from $35.00 to $33.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage currently has a “neutral” rating on the health services provider’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 24.58% from the stock’s previous close.

TDOC has been the topic of a number of other research reports. Barclays cut their price objective on shares of Teladoc Health from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 18th. SVB Leerink upgraded shares of Teladoc Health from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a report on Thursday, February 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 target price on shares of Teladoc Health in a research report on Thursday, February 23rd. StockNews.com raised shares of Teladoc Health to a “sell” rating in a research report on Friday, February 24th. Finally, SVB Securities raised shares of Teladoc Health from a “market perform” rating to an “outperform” rating and set a $34.00 target price for the company in a research report on Thursday, February 23rd. One analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus target price of $39.19.

Teladoc Health Stock Performance

Shares of TDOC stock opened at $26.49 on Monday. Teladoc Health has a 12 month low of $21.60 and a 12 month high of $77.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.13 and a quick ratio of 2.99. The firm has a market capitalization of $4.29 billion, a P/E ratio of -0.31 and a beta of 1.03. The company’s fifty day moving average price is $27.14 and its two-hundred day moving average price is $28.26.

Insider Transactions at Teladoc Health

In other news, insider Arnnon Geshuri sold 1,500 shares of the company’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $31.82, for a total value of $47,730.00. Following the completion of the sale, the insider now directly owns 74,317 shares of the company’s stock, valued at approximately $2,364,766.94. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, SVP Daniel Trencher sold 1,000 shares of the stock in a transaction that occurred on Friday, February 17th. The shares were sold at an average price of $30.21, for a total transaction of $30,210.00. Following the completion of the sale, the senior vice president now directly owns 20,408 shares of the company’s stock, valued at $616,525.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Arnnon Geshuri sold 1,500 shares of the stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $31.82, for a total transaction of $47,730.00. Following the sale, the insider now directly owns 74,317 shares of the company’s stock, valued at $2,364,766.94. The disclosure for this sale can be found here. In the last three months, insiders sold 5,340 shares of company stock valued at $156,332. Company insiders own 1.55% of the company’s stock.

Institutional Trading of Teladoc Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Teladoc Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 13,639,307 shares of the health services provider’s stock valued at $345,757,000 after acquiring an additional 78,859 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Teladoc Health by 879.2% in the 2nd quarter. Renaissance Technologies LLC now owns 4,475,319 shares of the health services provider’s stock valued at $148,625,000 after acquiring an additional 4,018,300 shares in the last quarter. State of Michigan Retirement System increased its stake in Teladoc Health by 1.2% in the 4th quarter. State of Michigan Retirement System now owns 3,783,000 shares of the health services provider’s stock valued at $89,468,000 after buying an additional 43,500 shares during the period. Geode Capital Management LLC increased its stake in Teladoc Health by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 2,169,548 shares of the health services provider’s stock valued at $51,309,000 after buying an additional 72,396 shares during the period. Finally, Himension Capital Singapore PTE. LTD. increased its stake in Teladoc Health by 67.7% in the 2nd quarter. Himension Capital Singapore PTE. LTD. now owns 2,167,552 shares of the health services provider’s stock valued at $71,984,000 after buying an additional 875,344 shares during the period. 84.14% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

(Get Rating)

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.